Q-omics provides the consensus-scored DEFB134 profile across patient tissues and cancer cell-line models. DEFB134 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, DEFB134 is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, DEFB134 RNA expression shows 11,313 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight UVM, THCA, and LIHC as cancer lineages where DEFB134 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB134 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB134 survival associations across molecular data types. DEFB134 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB134 RNA expression–survival associations across cancer types. High DEFB134 expression shows unfavorable associations in UVM, COAD, SCLC and PCPG, but favorable associations in THCA and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for DEFB134 RNA expression.
This table summarizes DEFB134 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for DEFB134. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFB134 shows lower tumor expression in PRAD and PAAD and higher tumor expression in THCA, BRCA and LUAD. The THCA box plot shows higher DEFB134 RNA expression in tumor versus normal tissue (log2 FC = +0.102, t-test p = .001).
This table shows molecular features associated with DEFB134 in patient tissues and cancer cell lines. In patient samples, DEFB134 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set. In cancer cell lines, DEFB134 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
